Engineered immune cells take on lupus in early trial
NCT ID NCT06038474
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE), an autoimmune disease. The treatment uses a patient's own immune cells that are modified in a lab to target and attack the faulty immune cells causing lupus. The main goals are to see if it is safe and to measure how well it controls disease activity. Only 6 adults with active lupus despite standard treatments are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profound Research LLC
Oceanside, California, 92056, United States
Conditions
Explore the condition pages connected to this study.